KOL Bulletin - FDA Approves Revtorpyk for HR+ / HER2– Metastatic Breast Cancer, but Logistical Hurdles May Restrict Uptake

FDA approved Revtorpyk (gedatolisib) on July 14, 2026, for HR-positive, HER2-negative locally advanced or metastatic breast cancer without a PIK3CA mutation following progression on or after prior endocrine therapy; efficacy was shown in the Phase 3 VIKTORIA-1 trial, where Revtorpyk combinations with fulvestrant, with or without palbociclib, improved median progression-free survival to 9.3 and 7.4 months versus 2 months for fulvestrant alone; logistical and commercialization challenges, including supply, pricing, and IV infusion requirements, may limit rapid uptake despite the first-in-class pan-PI3K/mTOR inhibitor profile.